Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What are you talking about now? This is the part where you never supply answers and just try to mock me instead. It's not working if you didn't notice.
LOL. I've said a dozen times here that I got the pub wrong but you dopes still try to club me with it just to make your own lousy records look a little better. Meanwhile JAMA is becoming ancient history. But the two dozen things I've called right there's no mention, of course.
...But it is funny the way you all gang up and twist it on me for simply wanting to see a simple current filing.
What chapter are you up to now in your Book of floppers?
I've seen a good number of 13g/d filings below the usual threshold. I recall seeing that Bigger NWBO filing years ago, I think it was a 13g?? Can't find it anywhere now. Bigger was around 2-1/2% when he bought in initially, but was diluted out of it.
http://edgar.secdatabase.com/613/92189518001584/filing-main.htm
That's the setting where it becomes apparent the stock has lost 99+% since inception.
>>hit classic view
That gonna hurt all that L business being done there. Eye rolls.
LOL. It wouldn't be an F it'd be a 13G or D. I forget when did Bigger enter, was it 2019?
>>What part of that don't you understand?
Means zero without a current filing. Just show the damn up to date filing, what's the big deal?
"Joe retired" is some dude. But I agree with him that someone needs to force a board seat.
Reposting some dude's claim is not the same as providing a filing.
You have no idea if he kept his investment.
You guys back to giving them bad information again, I see.
English please.
It's so bad that disciples here can't even verify if a few known shareholders are still holding.
Yeah, if you don't like losing 99.X% of your cash in style then go elsewhere! How stupid can you be.
What was the market cap back then?
Oil in Sawston.
Disciples giving out more bad information.
Call me lazy like that when I see on their home page they're still in the Plll mode, I don't feel the need to look any further.
I'd have to imagine that pestering disciple shareholders must be all over management for years now to change that home page, but management is unresponsive for some strange reason. Hmm
>>You need to look at the NEWS section of their website.
Still in the Phase lll stage waiting for results according to their home page. Can't make it up if you tried.
Something else in common with the lack of postings. LOL
"Public notification" or just to the BOD?
The replies to this one are remarkably measured.
I suspect the disciples were incessant in their ways to have them include L. But yes, that is pretty funny they don't mention the company. Pay to play?
>>I doubt anybody will actually pay for the report, so we will never see the full details.
The clearest signal that nothing was ever or currently is going on in terms of shareholder returns, is the once a year meet and greet with no investor quarterly calls. Perhaps one day, should they ever get things in gear, they'll hold a quarterly and that'll be the signal to jump in.
>>Dr Linda Liau, chair of neurosurgery, UCLA Health, commented: “This clinical trial represents a novel and potentially transformative approach to treating high-grade gliomas in children and young adults.
https://pmlive.com/pharma_news/ucla-launches-study-of-personalised-cancer-vaccine-in-paediatric-brain-tumours/
Here, you can all pull this one apart.
>>Asked whether the MHRA would eventually conduct its own full assessments of all new drugs, it said its priority was to “conduct a balance of national, collaborative and IRP reviews” – the collaborative reviews being Project Orbis and the Access Consortium.
https://pink.citeline.com/PS155263/UK-MHRA-To-Retain-Multiple-Approval-Pathways-From-2025
AI and disciples do have some things in common:
—
Before artificial intelligence can take over the world, it has to solve one problem. The bots are hallucinating
https://amp.cnn.com/cnn/2023/08/29/tech/ai-chatbot-hallucinations
Anyone else here think it strange that lack of conversation on message boards with both Marker and AlloVir. It's like they both vanished.
>>Investors in AlloVir should closely monitor the company’s progress as it explores strategic alternatives and works to chart a new course for the future. The outcome of this process will be a key determinant of the company’s long-term prospects and the potential value of its shares.
One more for the guy who thinks they're not at all connected.
>>Competing Interests: S.V., M.K., and Y.V. are consultants to AlloVir. V.H. holds Marker Therapeutics and AlloVir stock. N.L. is a consultant to Tessa Therapeutics. J.F.V. is a cofounder and equity holder in AlloVir and Marker Therapeutics and an employee of Marker Therapeutics, which aspires to commercialize the described approach. B.J.G. owns QBRegulatory Consulting which has consulting agreements with Tessa Therapeutics, Marker Therapeutics, LOKON, and AlloVir. H.E.H. is a co-founder with equity in Allovir and Marker Therapeutics, has served on advisory boards for Tessa Therapeutics, Kiadis, Novartis, Gilead Biosciences, Fresh Wind Biotechnologies and GSK, and received research support from Kuur Therapeutics and Tessa Therapeutics. C.M.R. has Stock and Other Ownership Interests with Coya, Bluebird Bio, Tessa Therapeutics, Marker Therapeutics, AlloVir, Walking Fish, Allogene Therapeutics, Memgen, Kuur Therapeutics, Bellicum Pharmaceuticals, TScan Therapeutics, Abintus Bio; Consulting or Advisory Role with Abintus Bio, Adaptimmune, Brooklyn Immunotherapeutic, Onk Therapeutics, Tessa Therapeutics, Memgen, Torque, Walking Fish Therapeutics, TScan Therapeutics, Marker Therapeutics, Turnstone Bio; and receives research funding from Kuur Therapeutics. A.M.L is a co-founder and equity holder for AlloVir and Marker Therapeutics and a consultant to AlloVir. P.L. is a member of the advisory board for Karyopharm. J.N. receives research support from Paxman Coolers Ltd. M.R. is a consultant to AstraZeneca, Macrogenics, Seagen and Novartis and receives research support from Pfizer. The remaining authors have no competing financial interests to disclose.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290161/
Here! Maybe this will make you think for a change.
>>Publisher’s Note
The May 1, 2021, article by Vasileiou et al entitled “T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects” (J Clin Oncol 10.1200/JCO.20.02224) was published online January 28, 2021, with errors.
The AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section read as:
No potential conflicts of interest were reported.
This section should have read as:
Spyridoula Vasileiou
Consulting or Advisory Role: AlloVir
Premal Lulla
Stock and Other Ownership Interests: Johnson Johnson (I)
Ifigeneia Tzannou
Stock and Other Ownership Interests: AlloVir
Ayumi Watanabe
Consulting or Advisory Role: AlloVir
Manik Kuvalekar
Consulting or Advisory Role: AlloVir
Mrinalini Bilgi
Employment: Carsgen Therapeutics Ltd
Carlos Ramos
Consulting or Advisory Role: Novartis
Research Funding: Tessa Therapeutics, Kuur Therapeutics (Inst)
Rayne Rouce
Honoraria: Novartis Pharmaceuticals UK Ltd., Kite/Gilead
Research Funding: Tessa Therapeutics (Inst)
Bambi Grilley
Employment: South Texas Nuclear Pharmacy (I), Q B Regulatory Consulting
Leadership: AlloVir
Stock and Other Ownership Interests: AlloVir
Travel, Accommodations, Expenses: Tessa Therapeutics
Juan Vera
Employment: Marker Therapeutics
Leadership: Marker Therapeutics, AlloVir
Stock and Other Ownership Interests: Marker Therapeutics, AlloVir
Consulting or Advisory Role: Marker Therapeutics, AlloVir
Research Funding: Marker Therapeutics
Patents, Royalties, Other Intellectual Property: I am an inventor in patents license to Marker Therapeutics Inc and Allovir. Marker Therapeutics, Inc. is currently advancing a T cell therapy in AML while Allovir is developing T cell therapies for viral infections.
Travel, Accommodations, Expenses: Marker Therapeutics, AlloVir
https://ascopubs.org/doi/10.1200/JCO.20.02224
It's not off topic that the whole point. Even admin knows it's not.
Wrong! The base science have commonalities thus Vera is a co-founder in both companies.
Frustrating, believe me, I know. Something like this will need to go down to ever find peace with this one, IMO.
https://www.prnewswire.com/news-releases/ronin-trading-and-sw-investment-management-issue-letter-to-stockholders-of-peregrine-pharmaceuticals-300487810.html
Not so fast! Vera is the CEO of Marker now. He's also the cofounder of both companies.
>>Other than Vera being a director of both, that’s the ONLY thing Marker and AlloVir have in common, so quit posting AlloVir here because they’ll keep getting deleted…
This strategy might help explain why you can't afford an iHub membership.
You know full well AlloVir is sitting on a mountain of cash that Marker needs desperately, and Vera can make that happen ( assuming Marker actually has a product worth investigating).
Good question. Could also be he's the only one with no interest in private CDMO's. It'd be good to know if the LG, Boynton, and the others had / have some kind of interest in Cognate and now Advent??
Then everything went dark as the cash dwindles.
>>Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified
Company to prioritize capital preservation and review strategic options
AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023